Abnormalities of signal transduction networks in chronic schizophrenia

Schizophrenia is a serious neuropsychiatric disorder characterized by disruptions of brain cell metabolism, microstructure, and neurotransmission. All of these processes require coordination of multiple kinase-mediated signaling events. We hypothesize that imbalances in kinase activity propagate through an interconnected network of intracellular signaling with potential to simultaneously contribute to many or all of the observed deficits in schizophrenia. We established a workflow distinguishing schizophrenia-altered kinases in anterior cingulate cortex using a previously published kinome array data set. We compared schizophrenia-altered kinases to haloperidol-altered kinases, and identified systems, functions, and regulators predicted using pathway analyses. We used kinase inhibitors with the kinome array to test hypotheses about imbalance in signaling and conducted preliminary studies of kinase proteins, phosphoproteins, and activity for kinases of interest. We investigated schizophrenia-associated single nucleotide polymorphisms in one of these kinases, AKT, for genotype-dependent changes in AKT protein or activity. Kinome analyses identified new kinases as well as some previously implicated in schizophrenia. These results were not explained by chronic antipsychotic treatment. Kinases identified in our analyses aligned with cytoskeletal arrangement and molecular trafficking. Of the kinases we investigated further, AKT and (unexpectedly) JNK, showed the most dysregulation in the anterior cingulate cortex of schizophrenia subjects. Changes in kinase activity did not correspond to protein or phosphoprotein levels. We also show that AKT single nucleotide polymorphism rs1130214, previously associated with schizophrenia, influenced enzyme activity but not protein or phosphoprotein levels. Our data indicate subtle changes in kinase activity and regulation across an interlinked kinase network, suggesting signaling imbalances underlie the core symptoms of schizophrenia.Disease mechanisms: A signaling imbalanceA study by US scientists indicates that changes in the activity of key signaling proteins may underlie core symptoms of schizophrenia. Protein kinases mediate the activation of intracellular signaling events and analyses of the kinome, the complete set of protein kinases encoded in the genome, previously revealed significant changes in phosphorylation patterns in postmortem brain tissue from patients with schizophrenia. Based on these findings, Jennifer McGuire at the University of Cincinnati and colleagues investigated the upstream regulation of these proteins. They identified both established and novel proteins associated with schizophrenia in the anterior cingulate cortex, with JNK and AKT activity being the most disrupted in schizophrenia patients. Their findings highlight how subtle changes in the activity of a small number of signaling proteins can propagate and have major consequences for mental health.

[1]  V. Haroutunian,et al.  Altered serine/threonine kinase activity in schizophrenia , 2014, Brain Research.

[2]  U. Alon,et al.  The incoherent feedforward loop can provide fold-change detection in gene regulation. , 2009, Molecular cell.

[3]  D. Bonchev,et al.  A Network Approach to Wound Healing. , 2013, Advances in wound care.

[4]  E. Coffey Nuclear and cytosolic JNK signalling in neurons , 2014, Nature Reviews Neuroscience.

[5]  R. Wolff,et al.  Influence of CHIEF pathway genes on gene expression: a pathway approach to functionality. , 2014, International journal of molecular epidemiology and genetics.

[6]  C. Hall,et al.  Regulation of Phosphorylation Pathways by p21 GTPases , 1996 .

[7]  Ralph J A Oude Ophuis,et al.  DMPK protein isoforms are differentially expressed in myogenic and neural cell lineages , 2009, Muscle & nerve.

[8]  R. Belmaker,et al.  Psychotropic drugs affect Ser9-phosphorylated GSK-3 beta protein levels in rodent frontal cortex. , 2006, The international journal of neuropsychopharmacology.

[9]  J. Milbrandt,et al.  The NIMA-family kinase Nek3 regulates microtubule acetylation in neurons , 2009, Journal of Cell Science.

[10]  P. Kaliman,et al.  Myotonic dystrophy protein kinase (DMPK) and its role in the pathogenesis of myotonic dystrophy 1. , 2008, Cellular signalling.

[11]  Shengying Qin,et al.  Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors , 2015, Tumor Biology.

[12]  E. Rozengurt,et al.  Protein kinase D complexes with C-Jun N-terminal kinase via activation loop phosphorylation and phosphorylates the C-Jun N-terminus , 2002, Oncogene.

[13]  Jian Zhou,et al.  Adenosine Kinase Expression in Cortical Dysplasia With Balloon Cells: Analysis of Developmental Lineage of Cell Types , 2015, Journal of neuropathology and experimental neurology.

[14]  V. Haroutunian,et al.  Increased G protein-coupled receptor kinase (GRK) expression in the anterior cingulate cortex in schizophrenia , 2014, Schizophrenia Research.

[15]  D. Lewis,et al.  Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction , 2004, Psychopharmacology.

[16]  J. Ferrell,et al.  Mechanisms of specificity in protein phosphorylation , 2007, Nature Reviews Molecular Cell Biology.

[17]  J. David Sweatt,et al.  Roles of serine/threonine phosphatases in hippocampel synaptic plasticity , 2001, Nature Reviews Neuroscience.

[18]  N. Lamb,et al.  Akt1 and Akt2: differentiating the aktion. , 2011, Histology and histopathology.

[19]  Tyrone D. Cannon How Schizophrenia Develops: Cognitive and Brain Mechanisms Underlying Onset of Psychosis , 2015, Trends in Cognitive Sciences.

[20]  V. Haroutunian,et al.  Glutamate transporter splice variant expression in an enriched pyramidal cell population in schizophrenia , 2015, Translational Psychiatry.

[21]  S. Willard,et al.  Glutamate, Glutamate Receptors, and Downstream Signaling Pathways , 2013, International journal of biological sciences.

[22]  J. Girault,et al.  DARPP-32, Jack of All Trades… Master of Which? , 2011, Front. Behav. Neurosci..

[23]  J Ludbrook,et al.  ADVANTAGES OF PERMUTATION (RANDOMIZATION) TESTS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY , 1994, Clinical and experimental pharmacology & physiology.

[24]  W. Maier,et al.  Further Evidence for Association of Variants in the AKT1 Gene with Schizophrenia in a Sample of European Sib-Pair Families , 2005, Biological Psychiatry.

[25]  Uri Alon,et al.  Dynamics and variability of ERK2 response to EGF in individual living cells. , 2009, Molecular cell.

[26]  J. Corradi,et al.  Altered Expression of CDC42 Signaling Pathway Components in Cortical Layer 3 Pyramidal Cells in Schizophrenia , 2015, Biological Psychiatry.

[27]  Stephen J Glatt,et al.  Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder: Convergent pathway analysis findings from two independent samples , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[28]  Anne Fernandez,et al.  Akt 1 and Akt 2 : Differentiating the aktion , 2011 .

[29]  J. Pratt,et al.  Novel treatment strategies for schizophrenia from improved understanding of genetic risk , 2014, Clinical genetics.

[30]  K. Stankovic,et al.  Metabolomic and Network Analysis of Pharmacotherapies for Sensorineural Hearing Loss , 2014, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[31]  L. Buée,et al.  Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy , 2013, Front. Mol. Neurosci..

[32]  Dong Sun Kim,et al.  AKT1 polymorphisms and survival of early stage non‐small cell lung cancer , 2012, Journal of surgical oncology.

[33]  Harvey J. Motulsky,et al.  Detecting outliers when fitting data with nonlinear regression – a new method based on robust nonlinear regression and the false discovery rate , 2006, BMC Bioinformatics.

[34]  J. Jaworski,et al.  Spatiotemporal Characterization of mTOR Kinase Activity Following Kainic Acid Induced Status Epilepticus and Analysis of Rat Brain Response to Chronic Rapamycin Treatment , 2013, PloS one.

[35]  Angus C Nairn,et al.  The DARPP-32/protein phosphatase-1 cascade: a model for signal integration 1 Published on the World Wide Web on 22 January 1998. 1 , 1998, Brain Research Reviews.

[36]  Yu Xue,et al.  GPS 2.1: enhanced prediction of kinase-specific phosphorylation sites with an algorithm of motif length selection. , 2011, Protein engineering, design & selection : PEDS.

[37]  D. Shaw,et al.  Genetic association of the AKT1 gene with schizophrenia in a British population , 2010, Psychiatric genetics.

[38]  J. Javitch,et al.  Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. , 2010, The American journal of psychiatry.

[39]  D. Gerrard,et al.  Effects of AMP-activated protein kinase (AMPK) signaling and essential amino acids on mammalian target of rapamycin (mTOR) signaling and protein synthesis rates in mammary cells. , 2014, Journal of dairy science.

[40]  C. Tamminga,et al.  Schizophrenia: Evidence implicating hippocampal GluN2B protein and REST epigenetics in psychosis pathophysiology , 2015, Neuroscience.

[41]  Lea Goentoro,et al.  Evidence that fold-change, and not absolute level, of beta-catenin dictates Wnt signaling. , 2009, Molecular cell.

[42]  J. Leek,et al.  Temporal dynamics and genetic control of transcription in the human prefrontal cortex , 2011, Nature.

[43]  Anthony Holland,et al.  Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain , 2004, The European journal of neuroscience.

[44]  Raquel E. Gur,et al.  Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia , 2014, Molecular Psychiatry.

[45]  Daniel J. Mount,et al.  Abnormal partitioning of hexokinase 1 suggests disruption of a glutamate transport protein complex in schizophrenia , 2014, Schizophrenia Research.

[46]  F. Fumagalli,et al.  Antipsychotic drug actions on gene modulation and signaling mechanisms. , 2009, Pharmacology & therapeutics.

[47]  C. Hall,et al.  Regulation of phosphorylation pathways by p21 GTPases. The p21 Ras-related Rho subfamily and its role in phosphorylation signalling pathways. , 1996, European Journal of Biochemistry.

[48]  Ladislav Stacho,et al.  Prediction of 492 human protein kinase substrate specificities , 2010, Proteome Science.

[49]  Gang Li,et al.  Protein kinase D: a new player among the signaling proteins that regulate functions in the nervous system , 2014, Neuroscience Bulletin.

[50]  G. Landreth,et al.  ERK2 Alone Drives Inflammatory Pain But Cooperates with ERK1 in Sensory Neuron Survival , 2015, The Journal of Neuroscience.

[51]  Vladimir I. Vladimirov,et al.  AKT1 Is Associated with Schizophrenia Across Multiple Symptom Dimensions in the Irish Study of High Density Schizophrenia Families , 2008, Biological Psychiatry.